Geron to present at two investor conferences in May 2026 to discuss its blood cancer treatments.

Geron Corporation announced that its management team will present at the Bank of America Securities 2026 Healthcare Conference on May 12 and the Stifel Virtual Targeted Oncology Forum on May 20. These presentations will provide updates on Geron's commercial-stage biopharmaceutical developments, including its approved telomerase inhibitor RYTELO® for certain blood cancers and ongoing Phase 3 trials. Investors can access live and archived webcasts on Geron's website. This engagement highlights Geron's efforts to advance treatments for blood cancer and keep investors informed on progress and clinical developments.